0.05 ML ranibizumab-eqrn 10 MG/ML Injection — RxCUI 2612684
RxNorm drug concept · Semantic clinical drug
RxCUI 2612684
Semantic clinical drug · SCD
● Current RxNorm concept 4 FDA products
4 package NDCs
Snapshot Jul 14, 2026
What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.
🗂️ Key Facts
RxCUI2612684
Official name0.05 ML ranibizumab-eqrn 10 MG/ML Injection
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
Also known asranibizumab-eqrn 0.5 MG per 0.05 ML Injection; ranibizumab-eqrn 0.5 MG in 0.05 ML Injection; ranibizumab-eqrn 10 MG/ML per 0.05 ML Injection
FDA products mapped4
Package NDCs mapped4
Reported Medicaid activity (SDUD)4,931 prescriptions · 20 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026
📖 Skip the Codes — Read It in Plain English.
Our pharmacist-built guide to Ranibizumab Injection: what it is, how it’s used, side effects, and interactions.
📗 Our plain-language guide HelloPharmacist
- It's blocking a protein called VEGF-A that tells blood vessels in your eye to grow in abnormal ways and leak fluid — both of which can damage your retina and blur your vision. By b...
- What exactly is ranibizumab doing inside my eye?
- Both contain ranibizumab, but they're delivered differently. Lucentis is given as a direct injection into the eye on a schedule your doctor sets. Susvimo is a small implant surgica...
- What's the difference between Lucentis and Susvimo?
🕸️ Concept Web — How 0.05 ML ranibizumab-eqrn 10 MG/ML Injection Connects
One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept
0.05 ML ranibizumab-eqrn 10 MG/ML Injection
RxCUI 2612684 Semantic clinical drug · SCD
Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.
-
Ingredients 2
The active substance itself — no strength, form, or brand attached yet.
-
Ranibizumab
595060IN -
Ranibizumab-eqrn
2612673PIN
-
Ranibizumab
-
Brand names 1
The same medicine's trade names. A brand name alone says nothing about strength or form.
-
Cimerli
2612677BN
-
Cimerli
-
Dose forms 9
The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.
-
Ranibizumab Injection
1724210SCDF -
Ranibizumab-eqrn Injection
2646157SCDFP -
Ranibizumab Injectable Product
1157901SCDG -
Ranibizumab-eqrn Injectable Product
2659217SCDGP -
Ranibizumab Injection [Cimerli]
2612680SBDF -
Ranibizumab-eqrn Injection [Cimerli]
2656342SBDFP -
Cimerli Injectable Product
2612679SBDG -
Injection
1649574DF - +1 more in this family
-
Ranibizumab Injection
-
Clinical & branded drugs 3
Ingredient + strength + dose form. These are the concepts real FDA products actually carry.
-
Ranibizumab-eqrn 10 MG/ML
2612683SCDC -
0.05 ML ranibizumab-eqrn 10 MG/ML Injection [Cimerli]
2612687SBD -
Ranibizumab-eqrn 10 MG/ML [Cimerli]
2612686SBDC
-
Ranibizumab-eqrn 10 MG/ML
Showing up to 8 concepts per family — 14 of 15 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.
🔀 Generic ⇄ Brand Crosswalk
The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.
Generic (Clinical) Concepts
-
Ranibizumab-eqrn 10 MG/ML
SCDC · 2612683 -
Ranibizumab Injection
SCDF · 1724210 -
Ranibizumab-eqrn Injection
SCDFP · 2646157 -
Ranibizumab Injectable Product
SCDG · 1157901 -
Ranibizumab-eqrn Injectable Product
SCDGP · 2659217
Brand-Name Concepts
-
0.05 ML ranibizumab-eqrn 10 MG/ML Injection [Cimerli]
SBD · 2612687 -
Ranibizumab-eqrn 10 MG/ML [Cimerli]
SBDC · 2612686 -
Ranibizumab Injection [Cimerli]
SBDF · 2612680 -
Ranibizumab-eqrn Injection [Cimerli]
SBDFP · 2656342 -
Cimerli Injectable Product
SBDG · 2612679 -
Cimerli
BN · 2612677
📦 FDA Products & Package NDCs
4 products · 4 package NDCs
4 package NDCs map to RxCUI 2612684 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
| Package NDC | Package | Brand / generic name | Labeler | Marketing start |
|---|---|---|---|---|
| 61314-0624-94 | 1 VIAL, SINGLE-DOSE in 1 CARTON (61314-624-94) / .05 mL in... | CIMERLI | Sandoz Inc | 2024-12-12 |
| 61314-0625-94 | 1 VIAL, SINGLE-DOSE in 1 CARTON (61314-625-94) / .05 mL in... | CIMERLI | Sandoz Inc | 2024-12-12 |
| 70114-0440-01 | 1 VIAL, SINGLE-DOSE in 1 CARTON (70114-440-01) / .05 mL in... | CIMERLI | Coherus BioSciences Inc | 2022-10-03 |
| 70114-0441-01 | 1 VIAL, SINGLE-DOSE in 1 CARTON (70114-441-01) / .05 mL in... | CIMERLI | Coherus BioSciences Inc | 2022-10-03 |
Observed labelers:
Coherus BioSciences Inc (2) ·
Sandoz Inc (2)
— this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.
🧾 Billing Codes (HCPCS)
Medical billing codes (HCPCS "J-codes") that connect to this concept's packages — used mostly when a clinic or hospital bills for a drug it administers. Each code links to its full billing page.
| Code | Descriptor | Mapped packages | Sources |
|---|---|---|---|
| Q5128 | Inj, cimerli, 0.1 mg | 4 | CMS |
⚠ A crosswalk is not coverage: an NDC↔HCPCS mapping does not guarantee any payer covers or pays the code. Always verify the current payer policy before billing.
🗃️ Sources & Limits
Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
- A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
- Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
- Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
- Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.
Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.